RISalud-ANDALUCÍA
Not a member yet
18682 research outputs found
Sort by
Connective tissue disease-associated interstitial lung disease treated with cyclophosphamide or rituximab: a unicentre, open-label and comparative study
No full textTo date, rheumatologists do not have curative treatments for connective tissue disease-associated interstitial lung disease (CTD-ILD), and therefore, stabilization of the disease is considered a therapeutic success. One of the most frequently used drugs for achieving this goal is Cyclophosphamide (CYC); however, in recent years, there has been increasing interest in the use of Rituximab (RTX) as a treatment for CTD-ILD. The objective of this study was to compare the long-term effectiveness of CYC versus RTX as treatments for patients with CTD-ILD. This was a unicenter, retrospective study analyzing clinical and imaging data of 26 CTD-ILD patients treated with CYC or RTX between June 2004 and December 2016. Baseline characteristics and baseline levels of Pulmonary Function Tests (PFTs) in both groups were compared using Fisher and T-student tests to ensure they were similar. The primary outcome of the study was the stabilization of PFTs or High-Resolution Tomography Computed Tomography (HRCT), with relapse defined as: a) a deterioration of ≥10% in Forced Vital Capacity (FVC), b) a decrease of ≥15% in Diffusing Capacity of Carbon Monoxide (DLCO), or c) worsening in HRCT. The prognostic effect of each treatment on stabilization was evaluated using the Kaplan-Meier method and the Log-Rank test.S
Vol. 30, nº 11. Calendario de vacunaciones e inmunizaciones de Andalucía 2025.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 10/2025 y acumulado desde la semana 01/2025. Datos provisionales. Incluye además el artículo titulado “Calendario de vacunaciones e inmunizaciones de Andalucía 2025”, de “David Moreno Pérez, Marta Bernal Sánchez-Arjona, Ignacio Salamanca de la Cueva, Daniel Ocaña Rodríguez, Inmaculada Martín Caballero, María Ángeles Onieva García, Javier Álvarez Aldeán, José Luis Barranco Quintana, Nicola Lorusso”.N
Vol. 30, nº 01-02. Badea y Gnoide. Herramientas para el acceso a las publicaciones estadísticas y cartográficas.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 01/2025 y acumulado desde la semana 01/2025. Datos provisionales. Incluye además el artículo titulado "Badea y Gnoide. Herramientas para el acceso a las publicaciones estadísticas y cartográficas”, de “Servicio de Estadísticas Sanitarias, Consejería de Salud y Consumo”.Ye
2024 Position Statement on Dietary Guidelines by SEEDO (Spanish Society for the Study of Obesity)
No full textLa obesidad es una enfermedad considerada epidémica debido a su alta prevalencia y se ha definido como compleja, crónica, recurrente y sin tratamiento curativo. Según la Encuesta Europea de Salud en España del año 2020 y la Encuesta Nacional de Salud 2017 (ENSE), la prevalencia de obesidad en personas adultas en España se sitúa en el 19,3 % en hombres y 18,0 % en mujeres, mientras que casi el 45 % de los hombres y el 31 % de las mujeres padecen sobrepeso. Uno de los grandes problemas de la obesidad es que actúa como gatillo para el desarrollo de enfermedades como diabetes mellitus (DM), hipertensión arterial (HTA), síndrome metabólico (SM), síndrome de apnea-hipoapnea del sueño (SAHS), enfermedad hepática metabólica, dislipidemia, enfermedad cardiovascular, ciertos tipos de cáncer y enfermedades psiquiátricas. El abordaje de esta enfermedad debe ser interdisciplinar, involucrando endocrinólogos, dietistas-nutricionistas, enfermería, expertos en ejercicio físico, cirujanos bariátricos, psicólogos, médicos de Atención Primaria y otros profesionales de la salud.Ye
Vol. 30, nº 25. Situación de la criptosporidiosis en el año 2023 y 2024 en la provincia de Cádiz.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 26/2025 y acumulado desde la semana 01/2025. Datos provisionales. Incluye además el artículo titulado “Situación de la criptosporidiosis en el año 2023 y 2024 en la provincia de Cádiz”, de “Yasmina Camacho Sánchez, María Cristina Rodríguez Rieiro, María Auxiliadora Fernández Gómez”.Ye
Vol. 30, nº 36. De los datos a la acción: situación del VIH y las ITS en el Distrito Jerez Costa-Noroeste.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 36/2025 y acumulado desde la semana 01/2025. Datos provisionales. Incluye además el artículo titulado “De los datos a la acción: situación del VIH y las ITS en el Distrito Jerez Costa-Noroeste”, de “Antonio Jesús Alcántara Flor”.Ye
Associations between degree of food processing and all-cause and cause-specific mortality: a multicentre prospective cohort analysis in 9 European countries.
No full textBackground: Ultra-processed food (UPF) consumption has been linked with higher risk of mortality. This multi-centre study investigated associations between food intake by degree of processing, using the Nova classification, and all-cause and cause-specific mortality.
Methods: This study analyzed data from the European Prospective Investigation into Cancer and Nutrition. All-cause mortality and cause-specific mortality due to cancer, circulatory diseases, digestive diseases, Parkinson's disease, and Alzheimer's disease served as endpoints. Hazard ratios (HRs) and 95% CIs were estimated using multivariable Cox proportional hazards regression models. Substitution analyses were also performed.
Findings: Overall, 428,728 (71.7% female) participants were included in the analysis and 40,016 deaths were documented after 15.9 years of follow-up. UPFs (in percentage grams per day [g/d]) were positively associated with all-cause mortality (HRs per 1-SD: 1.04; 95% CI: 1.02,1.05), as well as mortality from circulatory diseases (1.09; 95% CI: 1.07,1.12), cerebrovascular disease (1.11; 95% CI: 1.05,1.17), ischemic heart disease (1.10; 95% CI: 1.06,1.15), digestive diseases (1.12; 95% CI: 1.05,1.20), and Parkinson's disease (1.23; 95% CI: 1.06,1.42). No associations were found between UPFs and mortality from cancer or Alzheimer's disease. Replacing processed and UPFs with unprocessed/minimally processed foods was associated with lower mortality risk.
Interpretation: In this pan-European analysis, higher UPF consumption was associated with greater mortality from circulatory diseases, digestive diseases, and Parkinson's disease. The results support growing evidence that higher consumption of UPFs and lower consumption of unprocessed foods may have a negative impact on health.Ye
ACPA ARE ASSOCIATED WITH LOW BONE MINERAL DENSITY IN RHEUMATOID ARTHRITIS
No full textSeveral studies have related ACPA with the presence of bone erosion in rheumatoid arthritis (RA) patients, as they induce the differentiation and activation of osteoclasts. The main aim of this study was to evaluate the association of ACPA with bone mineral density (BMD) in RA. A case-control study was conducted including 73 RA patients (2010 EULAR criteria) with a long-standing disease duration of 5 years. Demographic and clinical variables were collected, and BMD values were measured using densitometry at the lumbar spine (CL), hip (CT), and femoral neck (CF). The presence of low BMD (osteopenia: t-score ≤ -1) and ACPA levels were compared using logistic regression analysis, adjusting for variables related to BMD such as age, sex, menopause, body mass index (BMI), smoking habits, disease duration, daily corticosteroid doses, methotrexate treatment, and inflammatory disease activity (DAS28). The study included 73 patients (14 men) with a mean age of 66.45 ± 10.41 years, mean BMI of 28.48 ± 5.22 kg/m², mean disease duration of 2.28 ± 1.75 years, and a mean DAS28 score of 3.17 ± 1.18. Of these, 29 patients were ACPA-negative and 44 were ACPA-positive. Osteopenia was found in 82.2% of patients at the lumbar spine, 65.8% at the hip, and 75.3% at the femoral neck. Logistic regression analysis did not show a statistically significant association between osteopenia and inflammatory activity (DAS28), vitamin D levels, or positive rheumatoid factor, after adjusting for variables that can influence BMD.S
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.
No full textBackground: Adjuvant immune checkpoint inhibition (ICI) with anti-PD-1 antibodies in high-risk resected melanoma has been shown to improve recurrence-free survival. It is unclear whether prior adjuvant anti-PD-1 therapy is associated with altered response to subsequent ICI treatment in the metastatic setting. Methods: Using data from the European Melanoma Registry (EUMelaReg), we analyzed the efficiency of first-line (1L) ICI in non-resectable or metastatic melanoma after failure from prior adjuvant anti-PD-1 treatment. Both single-agent anti-PD-1 and combined anti-PD-1/CTLA-4 (Ipi/Nivo) 1L regimes were included in the analysis. We identified 389 patients receiving 1L ICI with prior adjuvant anti-PD-1 treatment. The control population was selected from a pool of 3390 PD-1-naive cases by 1:1 matching for the type of 1L ICI and various prognostic factors. As outcome measure, overall remission rates (ORR) were calculated and progression-free survival (PFS) was evaluated by Kaplan-Meier and Cox regression analysis. Results: Out of 389 patients, 303 (77.9 %) received Ipi/Nivo and 86 (22.1 %) anti-PD-1 in 1L. ORR was significantly lower in pre-treated patients (31.4 %) as compared to anti-PD-1 naive patients (48.8 %; p < 0.0001). Kaplan-Meier analysis showed significantly shorter median PFS for pre-treated patients. This applied to both anti-PD-1 and Ipi/Nivo treatment. Patients with early recurrence from adjuvant treatment (during or up to 12 weeks after end of treatment) showed lower ORR (28.5 %) and shorter PFS (3.1 months) than those who recurred later (37.7 % and 6.1 months, respectively). Conclusions: Patients with metastatic melanoma, previously exposed to anti-PD-1 ICI in the adjuvant setting showed significantly lower ORR and shorter PFS to 1L ICI with either Ipi/Nivo or single-agent anti-PD-1 retreatment.Ye
Vol. 30, nº 15. Virus del Nilo Occidental en Andalucía: año 2024.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 14/2025 y acumulado desde la semana 01/2025. Datos provisionales. Incluye además el artículo titulado “Virus del Nilo Occidental en Andalucía: año 2024”, de “Servicio de Vigilancia y Salud Laboral”.Ye